Hierarchical Data-Driven Analysis of Clinical Symptoms Among Patients With Parkinson's Disease
暂无分享,去创建一个
Y. Benjamini | K. Marder | A. Mirelman | Nir Giladi | S. Bressman | T. Galili | T. Gurevich | Alexis Mitelpunkt | Netta Shachar | Mira Marcus-Kalish | A. Orr-Urtreger | A. Thaler | T. Kozlovski | M. Gana‐Weisz | Tal Galili
[1] K. Marder,et al. Progression in the LRRK2-Asssociated Parkinson Disease Population , 2018, JAMA neurology.
[2] R. Lipton,et al. Cognitive and motor functioning in elderly glucocerebrosidase mutation carriers , 2017, Neurobiology of Aging.
[3] Jian-jun Liu,et al. Screening for TMEM230 mutations in young-onset Parkinson's disease , 2017, Neurobiology of Aging.
[4] A. Mirelman,et al. A "dose" effect of mutations in the GBA gene on Parkinson's disease phenotype. , 2017, Parkinsonism & related disorders.
[5] K. Marder,et al. Neuropsychiatric characteristics of GBA-associated Parkinson disease , 2016, Journal of the Neurological Sciences.
[6] E. Tolosa,et al. Motor and nonmotor heterogeneity of LRRK2‐related and idiopathic Parkinson's disease , 2016, Movement disorders : official journal of the Movement Disorder Society.
[7] Christine B. Peterson,et al. Many Phenotypes Without Many False Discoveries: Error Controlling Strategies for Multitrait Association Studies , 2015, Genetic epidemiology.
[8] K. Marder,et al. REM sleep behavior disorder, as assessed by questionnaire, in G2019S LRRK2 mutation PD and carriers , 2015, Movement disorders : official journal of the Movement Disorder Society.
[9] K. Marder,et al. Age-specific penetrance of LRRK2 G2019S in the Michael J. Fox Ashkenazi Jewish LRRK2 Consortium , 2015, Neurology.
[10] J. Duda,et al. Motor phenotype of LRRK2‐associated Parkinson's disease: A tunisian longitudinal study , 2015, Movement disorders : official journal of the Movement Disorder Society.
[11] K. Marder,et al. Olfactory identification in LRRK2 G2019S mutation carriers: a relevant marker? , 2014, Annals of clinical and translational neurology.
[12] W. Chung,et al. Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes. , 2014, JAMA neurology.
[13] K. Johansen,et al. Olfactory dysfunction in sporadic Parkinson's Disease and LRRK2 carriers , 2014, Acta neurologica Scandinavica.
[14] J. Trinh,et al. A comparative study of Parkinson's disease and leucine-rich repeat kinase 2 p.G2019S parkinsonism , 2014, Neurobiology of Aging.
[15] Yoav Benjamini,et al. Selective inference on multiple families of hypotheses , 2014 .
[16] P. Mazzoni,et al. Parkinson disease phenotype in Ashkenazi jews with and without LRRK2 G2019S mutations , 2013, Movement disorders : official journal of the Movement Disorder Society.
[17] Nir Giladi,et al. Fall risk and gait in Parkinson's disease: The role of the LRRK2 G2019S mutation , 2013, Movement disorders : official journal of the Movement Disorder Society.
[18] K. Marder,et al. Cognitive performance of GBA mutation carriers with early-onset PD , 2012, Neurology.
[19] J. Duda,et al. Cognitive dysfunction in Tunisian LRRK2 associated Parkinson's disease. , 2012, Parkinsonism & related disorders.
[20] David Firth,et al. Multinomial logit bias reduction via the Poisson log-linear model , 2011 .
[21] D. Berg,et al. GBA-associated PD presents with nonmotor characteristics , 2011, Neurology.
[22] A. Lang,et al. Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers , 2011, Neurology.
[23] Yoav Benjamini,et al. Simultaneous and selective inference: Current successes and future challenges , 2010, Biometrical journal. Biometrische Zeitschrift.
[24] E. Sidransky,et al. MUTATIONS IN GBA ARE ASSOCIATED WITH FAMILIAL PARKINSON DISEASE SUSCEPTIBILITY AND AGE AT ONSET , 2009, Neurology.
[25] M. Nalls,et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. , 2009, The New England journal of medicine.
[26] A. Singleton,et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. , 2009, Brain : a journal of neurology.
[27] T. Foroud,et al. Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset , 2009, Neurology.
[28] E. Tolosa,et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study , 2008, The Lancet Neurology.
[29] Chiou-Lian Lai,et al. Cognitive and Motor Components of Response Speed in the Stroop Test in Parkinson's Disease Patients , 2008, The Kaohsiung journal of medical sciences.
[30] Geert Mayer,et al. The REM sleep behavior disorder screening questionnaire—A new diagnostic instrument , 2007, Movement disorders : official journal of the Movement Disorder Society.
[31] Paolo Barone,et al. International multicenter pilot study of the first comprehensive self‐completed nonmotor symptoms questionnaire for Parkinson's disease: The NMSQuest study , 2006, Movement disorders : official journal of the Movement Disorder Society.
[32] M. Farrer,et al. Clinical traits of LRRK2-associated Parkinson's disease in Ireland: a link between familial and idiopathic PD. , 2005, Parkinsonism & related disorders.
[33] Mathias Toft,et al. Clinical features of LRRK2‐associated Parkinson's disease in central Norway , 2005, Annals of neurology.
[34] Johan Marinus,et al. Assessment of autonomic dysfunction in Parkinson's disease: The SCOPA‐AUT , 2004, Movement disorders : official journal of the Movement Disorder Society.
[35] M. Burns,et al. Case-Control Study , 2020, Definitions.
[36] T. Tombaugh. Trail Making Test A and B: normative data stratified by age and education. , 2004, Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists.
[37] R A Steer,et al. Use of the Beck Depression Inventory-II with depressed geriatric inpatients. , 2000, Behaviour research and therapy.
[38] Y. Benjamini,et al. On the Adaptive Control of the False Discovery Rate in Multiple Testing With Independent Statistics , 2000 .
[39] A. Bonnet,et al. [The Unified Parkinson's Disease Rating Scale]. , 2000, Revue neurologique.
[40] A. Tröster,et al. Lexical, semantic, and action verbal fluency in Parkinson's disease with and without dementia. , 1999, Journal of clinical and experimental neuropsychology.
[41] P. Hobson,et al. Use of the GDS-15 geriatric depression scale as a screening instrument for depressive symptomatology in patients with Parkinson's disease and their carers in the community. , 1999, Age and ageing.
[42] P. Satz,et al. Normative data stratified by age and education for the Neuropsychological Screening Battery for Hispanics (NeSBHIS): Initial report , 1996, Journal of the International Neuropsychological Society.
[43] D. Firth. Bias reduction of maximum likelihood estimates , 1993 .
[44] J. Hughes,et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.
[45] R. Doty,et al. Internal consistency reliability of the fractionated and whole University of Pennsylvania Smell Identification Test , 1989, Perception & psychophysics.
[46] R. Simes,et al. An improved Bonferroni procedure for multiple tests of significance , 1986 .
[47] C. Spielberger,et al. Psychometric properties of the STAI: a reply to Ramanaiah, Franzen, and Schill. , 1984, Journal of personality assessment.